Pelthos Therapeutics Inc.

Day range

$16.10 – $17.34

Open

$17.34

Prev close

$17.00

Volume

12.9K

Market cap

$65.08M

Shares out

3.83M

P/E

—

P/S

1.50

P/B

-43.36

P/FCF

—

ROE

5755.6%

ROA

-62.9%

Debt/Equity

-46.58

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsOct 1, 2026

  On September 29, 2026, the Company held its 2026 Annual Meeting. ... The eight (8) nominees named in the Proxy Statement were elected to serve as the Company's directors until the Company's 2027 Annual Meeting of Stockholders, or until each of their respective successors are elected and qualified or until their earlier resignation or removal.

• Internal control weaknessAug 13, 2026

  In connection with this restatement, the Company has concluded that the misapplication of ASC 820 resulted from a material weakness in its internal control over financial reporting that existed as of March 31, 2026, and which continues to exist. The material weakness relates to controls over the valuation and review of Level 3 fair value measurements associated with the Company's convertible debt.

• Financial restatementAug 13, 2026

  Readers are encouraged to review the Company's Current Report on Form 8-K filed under Item 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review), which describes the Company's determination that its previously issued condensed consolidated financial statements for the quarter ended March 31, 2026 should no longer be relied upon and should be restated.

• Investor presentationMay 28, 2026

  On May 28, 2026, Pelthos Therapeutics Inc. (the "Company") issued a press release announcing that its Chief Executive Officer, Scott Plesha, will present and participate in one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 in New York, New York. A copy of the presentation is attached hereto as Exhibit 99.2.

• Cfo departureMay 21, 2026

  As previously disclosed, the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026. On May 15, 2026, the Company entered into a Separation and Release Agreement with Mr. Knuettel to clarify the terms applicable to Mr. Knuettel's separation from the Company.

Days to cover

4.1

Short interest

104.57K

Avg volume

25.69K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
  neutralGlobeNewswire Inc.· Jul 24, 2026
• Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
  positiveGlobeNewswire Inc.· May 28, 2026
• Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
  positiveBenzinga· Jan 5, 2026
• Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
  positiveGlobeNewswire Inc.· Dec 23, 2025
• Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
  positiveGlobeNewswire Inc.· Dec 9, 2025